{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:58:25Z","timestamp":1777478305282,"version":"3.51.4"},"reference-count":27,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2905,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C &amp;lt;6.5% (48 mmol\/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean A1C &amp;lt;6.5% were analyzed with linear regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Median A1C in the whole population was 6.4% at baseline; at 5 years, it was 6.2% with glargine treatment and 6.5% with standard care. Of those with diabetes at baseline, 60% using glargine and 45% using standard care had A1C &amp;lt;6.5% at 5 years. Lack of diabetes and lower baseline A1C were independently associated with 5-year mean A1C &amp;lt;6.5%. Maintaining mean A1C &amp;lt;6.5% was more likely with glargine (odds ratio [OR] 2.98 [95% CI 2.67\u20133.32], P &amp;lt; 0.001) than standard care after adjustment for other independent predictors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Systematic intervention with basal insulin glargine or standard care early in the natural history of dysglycemia can maintain glycemic control near baseline levels for at least 5 years, whether diabetes is present at baseline or not. Keeping mean A1C &amp;lt;6.5% is more likely in people with lower baseline A1C and with the glargine-based regimen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-2238","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T03:55:39Z","timestamp":1368071739000},"page":"2915-2922","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":26,"title":["Characteristics Associated With Maintenance of Mean A1C &amp;lt;6.5% in People With Dysglycemia in the ORIGIN Trial"],"prefix":"10.2337","volume":"36","author":[{"name":"The ORIGIN Trial Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,9,14]]},"reference":[{"key":"2022031221335322100_B1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2022031221335322100_B2"},{"key":"2022031221335322100_B3","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2022031221335322100_B4","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00125-010-1871-0","article-title":"Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study","volume":"53","author":"Gerstein","year":"2010","journal-title":"Diabetologia"},{"key":"2022031221335322100_B5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031221335322100_B6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031221335322100_B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"2022031221335322100_B9","first-page":"579","article-title":"Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy","volume":"59","author":"Hadden","year":"1986","journal-title":"Q J Med"},{"key":"2022031221335322100_B10"},{"key":"2022031221335322100_B11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B12"},{"key":"2022031221335322100_B13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"ORIGIN Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B15","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221335322100_B16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"2022031221335322100_B17","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031221335322100_B20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/diacare.27.7.1535","article-title":"The burden of treatment failure in type 2 diabetes","volume":"27","author":"Brown","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031221335322100_B21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/dc09-1749","article-title":"Secondary failure of metformin monotherapy in clinical practice","volume":"33","author":"Brown","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031221335322100_B22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ecl.2012.03.003","article-title":"Reevaluating goals of insulin therapy: perspectives from large clinical trials","volume":"41","author":"Riddle","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2022031221335322100_B23","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221335322100_B24","unstructured":"World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Available at http:\/\/www.who.int\/diabetes\/publications\/diagnosis_diabetes2011\/en\/index.html. Accessed 1 September 2011"},{"key":"2022031221335322100_B25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jama.281.6.558","article-title":"Midlife hand grip strength as a predictor of old age disability","volume":"281","author":"Rantanen","year":"1999","journal-title":"JAMA"},{"key":"2022031221335322100_B26","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s00125-012-2701-3","article-title":"Moderate alcohol consumption is associated with improved insulin sensitivity, reduced basal insulin secretion rate and lower fasting glucagon concentration in healthy women","volume":"55","author":"Bonnet","year":"2012","journal-title":"Diabetologia"},{"key":"2022031221335322100_B27","doi-asserted-by":"crossref","first-page":"b5444","DOI":"10.1136\/bmj.b5444","article-title":"The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study","volume":"340","author":"Miller","year":"2010","journal-title":"BMJ"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/10\/2915\/615129\/2915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/10\/2915\/615129\/2915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:50:39Z","timestamp":1647129039000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/10\/2915\/30482\/Characteristics-Associated-With-Maintenance-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,14]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,14]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2238","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,14]]}}}